Gunderson Dettmer represented client Medrio, a leading provider of eClinical technology to pharmaceutical, biotech, medical device, diagnostics, and animal health markets, in its acquisition of HMD Clinical. The acquisition will enable Medrio to expand its portfolio of proven eClinical technology solutions and integrate HMD’s expertise in Randomization and Trial Supply Management (RTSM) with Medrio’s expertise in electronic data capture.

In the announcement of the transaction, CFO of Medrio Ed Gould said, “Our long-standing partnership with HMD Clinical and existing integrations will ensure a smooth transition for customers. Both HMD and Medrio pride themselves on having developed flexible technology, and as such system integration has gone smoothly. As we look to continue to grow our organization, HMD Clinical’s portfolio, culture, and mission-aligned with ours, and ultimately will allow us to continue to offer best-in-class service and technology solutions to our customers.”

The Gunderson deal team was led by Matthew Martinez and included Bennett Yee, Nicholas Markman and Amy Luong.